The Biosimilars Forum said this week that if Congress enacted certain changes, the federal government and beneficiaries could save billions of dollars in Medicare Part B.
The Biosimilars Forum said this week that if Congress enacted certain changes, the federal government and beneficiaries could save billions of dollars in Medicare Part B.
The industry group said it commissioned a scoring analysis from Avalere Health examining options that could potentially reduce out-of-pocket costs (OOP) and federal spending in the range of $1.9 billion to $5.2 billion between 2020 and 2029, and cut beneficiary costs by $2.2 billion to $3.3 billion.
These actions could propel market share for biosimilars to 26% to 46% of the market. The group said their proposal follows the administration’s 2020 budget proposal that calls for “harnessing payment and cost-sharing incentives to increase biosimilar adoption.”
“It’s clear that incentivizing biosimilars will lower health care costs for patients and taxpayers,” said Juliana Reed, president of the Biosimilars Forum, in a statement. “Today’s scoring analysis proves that biosimilars need to be part of the solution to lower healthcare costs, but it will require proactive policy action to unlock these savings.”
The Avalere analysis was based on a range of assumptions. For instance, Congress could require CMS to use the Center for Medicare and Medicaid Innovation (CMMI) to create models designed to increase access to biosimilars, including a shared savings model. Medicare savings stemming from prescribing a biosimilar, as compared to a reference biologic, would be shared with providers.
Using 3 assumptions of a low, medium, and high provider-induced demand assumption, the shared savings program for providers in Medicare Part B would result in a budget-neutral outcome of $0 billion to a $3 billion decrease over the fiscal year 2020-2029 budget window. Average biosimilar market share is projected to reach 27% to 54% of the market, depending on the scenario.
Another option could involve using an additional add-on payment. This could save $8.2 billion in health costs over the time frame. This policy would incentivize doctors to prescribe biosimilars by increasing the amount they are paid in Medicare Part B.
Current proposals under consideration in Congress include a measure in the Senate to improve the Purple Book, crack down on patent abuses, and increase the amount of biosimilar education.
Part 3: BioRationality—FDA Webinar on Biosimilars Efficacy Testing Marks Major Step Forward
September 20th 2023In the final part of a 3-part series, Sarfaraz K. Niazi, PhD, gives his take on the FDA's recent workshop dedicated to streamlining biosimilar development and his opinion on what the industry can learn from the webinar presenters.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Part 1: FDA Workshop Highlights Global Regulatory View on Biosimilar Development
September 13th 2023An FDA workshop featuring regulators from around the world provided the regulatory perspective on how each government determines whether a biosimilar is clinically equivalent to their reference product, highlighting the science behind their development guidelines.
How Community Oncologists Can Break Down Biosimilar Adoption Barriers
March 19th 2023On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.
Stelara and Enbrel Chosen for IRA Price Negotiation
August 29th 2023Stelara (ustekinumab) and Enbrel (etanercept), 2 originator medications that will face biosimilar competition within the next decade, were among the 10 preliminary drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA).
2 Clarke Drive
Cranbury, NJ 08512